Enadenotucirev
Enadenotucirev is an investigational oncolytic virus that is in clinical trials for various cancers.[1]
It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as ColoAd1.[2]
Enadenotucirev has also been modified with additional genes using the tumor-specific immuno-gene therapy (T-SIGn) platform to develop novel cancer gene therapy agents.
The T-SIGn vectors at clinical study stage are:
- NG-350A: This vector contains two transgenes expressing the heavy and light chains for a secreted CD40 agonist monoclonal antibody.
- NG-641: This vector contains four transgenes expressing secreted Interferon alpha, the chemokines CXCL9, CXCL10 and an anti-FAP/anti-CD3 bispecific T-cell activator
In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) designated enadenotucirev as an orphan medicinal product for the treatment of ovarian cancer.[3]
Clinical trials[edit | edit source]
Two clinical trials have been completed with enadenotucirev. The EVOLVE study [4] and the MOA study.[5]
As of June 2019[update], there are two active phase 1 trials: OCTAVE (in ovarian cancer)[6] and SPICE (in multiple solid tumor indications) [7]
Of the T-SIGn viruses, NG-350A has an ongoing clinical study.[8]
See also[edit | edit source]
References[edit | edit source]
- ↑ "Enadenotucirev". PsiOxus Therapeutics. Retrieved 2019-07-04.
- ↑
- ↑ "EMA grants positive opinion for orphan drug status for ovarian cancer oncolytic vaccine". PsiOxus Therapeutics. 2015-01-13. Retrieved 2019-07-04.
- ↑ Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients (EVOLVE)
- ↑ Mechanism of Action Trial of ColoAd1 (MOA)
- ↑ Phase I / II Study Of Enadenotucirev Intraperitoneally in Ovarian Cancer Patients (OCTAVE)
- ↑ Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors (SPICE)
- ↑ First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD